Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Permanent URI for this collectionhttps://hdl.handle.net/11147/7148
Browse
4 results
Search Results
Article Development and Evaluation of 177Lu-Imatinib: Radiolabeling and Cell Culture Studies(Walter de Gruyter GmbH, 2025) Ozgenc, E.; Karpuz, M.; Guler, G.; Burak, Z.; Başpainar, Y.; Gundogdu, E.A.Targeted radiopharmaceuticals offer promising approaches for cancer diagnosis and therapy. This study developed freeze-dried kit formulations of 177Lu-Imatinib (IMT) and evaluated their potential efficacy through in vitro studies. Four formulations (F1-F4) containing IMT and chelating agents were prepared and characterized via Fourier transform infrared (FTIR), ultraviolet spectrum (UV), and thermogravimetric analysis (TGA) to confirm complex formation. Biocompatibility was assessed in NIH-3T3 cells using the MTT assay. Radiolabeling with 177Lu was optimized by varying pH, incubation time, and reactant ratios. Radiochemical purity and stability were analyzed over 7 days using HPLC. Binding affinity and cytotoxicity were evaluated in MCF-7 and NIH-3T3 cells. Spectroscopic analyses confirm successful complex formation. All formulations exhibited >90% viability in NIH-3T3 cells. Optimal radiolabeling conditions (45mg IMT-chelator, pH 5, 60min incubation) yielded >90% efficiency, with stable radiolabeling for 7 days. The 177Lu-IMT-DOTA (F3) formulation showed significantly higher binding and cytotoxic effects in MCF-7 cells compared to controls. The 177Lu-IMT-DOTA (F3) kit demonstrates high radiolabeling efficiency, stability, and selective in vitro cytotoxicity toward breast cancer cells, supporting its potential as a targeted radiopharmaceutical. © 2025 Walter de Gruyter GmbH, Berlin/Boston 2025.Article Cx32 Cellular Localization Is Related To Epithelial To Mesenchymal Transition in Breast Cells(Pleiades Publishing inc, 2025) Oz, Sercan; Turan, Fatma Basak; Yondem, Eyup; Pesen-Okvur, Devrim; Yalcin-Ozuysal, Ozden; Ozcivici, Engin; Mese, GulistanConnexins (Cx) play both gap junction-related and -independent roles in cells, and their localization is essential for their function in cellular processes. Besides membrane localization, connexins can also be localized to the cytoplasm and nucleus, especially in cancer cells. The differential localization of connexins including Cx32 was observed in different stages of cancers. Cx32 was upregulated and observed in cytoplasms of cells in lymph-node metastasis of breast cancer samples compared to primary tumors. However, the significance of the increase in Cx32 expression and alteration of Cx32 cellular localization in epithelial-to-mesenchymal transition (EMT) is not known. To determine if Cx32 overexpression and/or localization over one week would induce the EMT process, we first examined the cellular localization of Cx32 in MCF10A and MDA-MB-231 cells at different time points using Western blot and RT-PCR as well as immunostaining with confocal microscopy. Then, we correlated the changes of Cx32 expression and localization with EMT marker expression. We showed that Cx32 had altered cellular localization and Cx32 overexpression increased Slug levels while it reduced E-cadherin and Snail expression in MDA-MB-231 for 7 days. In contrast, E-cadherin and Vimentin were reduced in MCF10A-Cx32 cells compared with controls over 7 days, and the expression pattern for nuclear Cx32 and Zeb2 was following similar pattern in MCF10A cells. Our results suggest a previously unknown time-dependent relation between Cx32 and the regulation of the EMT process.Article Comprehensive Analysis Of<i> Gjb1</I> in Breast Cancer: Its Implications in Survival and Molecular Mechanisms(int inst Anticancer Research, 2024) Ozcivici, Engin; Mese, GulistanBackground/Aim: Breast cancer is the leading cause of cancer-related mortality among women worldwide. The connexin (Cx) family, including GJB1 (Cx32), plays complex roles in tumor progression depending on cellular context and cancer subtype. While Cx32 overexpression has been linked to lymph node metastasis, its effects on survival and molecular processes remain unclear. Herein, we aimed to investigate the role of GJB1 in breast cancer by examining its impact on survival and cellular processes in addition to its expression pattern in tumor subtypes, using public datasets. Materials and Methods: We conducted a comprehensive analysis of GJB1 in breast cancer using METABRIC patient dataset, Cancer Cell Line Encylopedia, and other publicly available databases. We examined the association between GJB1 expression and patient survival, performed differential gene expression analysis, and explored gene set enrichment to identify biological processes associated with high GJB1 expression. Results: GJB1 was significantly down-regulated in breast cancer tissues compared to normal tissues. However, patients with high GJB1 expression had significantly poorer survival compared to those with low expression, with the median survival reduced by over 25 months. Gene ontology (GO) analysis revealed that down- regulated genes in the GJB1-high group were enriched in extracellular matrix components and membrane junctions, while up-regulated genes were associated with mitochondrial function and cellular respiration. Conclusion: Our findings suggest a dual role for GJB1 in breast cancer. Although it is generally down-regulated, high GJB1 expression is associated with poorer survival, implying a potential oncogenic role. Further studies are needed to clarify the role of GJB1 in breast cancer and explore its therapeutic implications.Article Citation - Scopus: 13Her2-Targeted, Degradable Core Cross-Linked Micelles for Specific and Dual Ph-Sensitive Dox Release(John Wiley and Sons Inc, 2022) Bayram, N.N.; Ulu, G.T.; Topuzoğulları, M.; Baran, Y.; Dinçer, İşoğlu, S.Here, a targeted, dual-pH responsive, and stable micelle nanocarrier is designed, which specifically selects an HER2 receptor on breast cancer cells. Intracellularly degradable and stabilized micelles are prepared by core cross-linking via reversible addition−fragmentation chain-transfer (RAFT) polymerization with an acid-sensitive cross-linker followed by the conjugation of maleimide–doxorubicin to the pyridyl disulfide-modified micelles. Multifunctional nanocarriers are obtained by coupling HER2-specific peptide. Formation of micelles, addition of peptide and doxorubicin (DOX) are confirmed structurally by spectroscopical techniques. Size and morphological characterization are performed by Zetasizer and transmission electron microscope (TEM). For the physicochemical verification of the synergistic acid-triggered degradation induced by acetal and hydrazone bond degradation, Infrared spectroscopy and particle size measurements are used. Drug release studies show that DOX release is accelerated at acidic pH. DOX-conjugated HER2-specific peptide-carrying nanocarriers significantly enhance cytotoxicity toward SKBR-3 cells. More importantly, no selectivity toward MCF-10A cells is observed compared to HER2(+) SKBR-3 cells. Formulations cause apoptosis depending on Bax and Caspase-3 and cell cycle arrest in G2 phase. This study shows a novel system for HER2-targeted therapy of breast cancer with a multifunctional nanocarrier, which has higher stability, dual pH-sensitivity, selectivity, and it can be an efficient way of targeted anticancer drug delivery. © 2021 Wiley-VCH GmbH